Tandem Diabetes Care (BSP:T2ND34) Other Current Liabilities: R$697 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BSP:T2ND34 Tandem Diabetes Care Inc BSP:T2ND34
49 GF Score
Price R$5.98
GF Value R$8.36
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Tandem Diabetes Care Other Current Liabilities?

Tandem Diabetes Care BSP:T2ND34 -1.02% 49 Other Current Liabilities is R$697 Mil as of Jun. 2026. GuruFocus rates BSP:T2ND34 with a GF Score™ of 49/100 and a GF Value™ of R$8.36 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Tandem Diabetes Care's other current liabilities for the quarter that ended in Jun. 2026 was R$697 Mil.

Tandem Diabetes Care's quarterly other current liabilities declined from Dec. 2025 (R$771 Mil) to Mar. 2026 (R$730 Mil) and declined from Mar. 2026 (R$730 Mil) to Jun. 2026 (R$697 Mil).

Tandem Diabetes Care's annual other current liabilities increased from Dec. 2023 (R$349 Mil) to Dec. 2024 (R$701 Mil) and increased from Dec. 2024 (R$701 Mil) to Dec. 2025 (R$771 Mil).

Tandem Diabetes Care Other Current Liabilities Related Terms

Tandem Diabetes Care Other Current Liabilities Historical Data

* Premium members only.

The historical data trend for Tandem Diabetes Care's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tandem Diabetes Care Other Current Liabilities Chart

Tandem Diabetes Care Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 417.44 359.06 349.22 700.82 771.25

Tandem Diabetes Care Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 827.87 859.21 771.25 730.02 696.90
BSP:T2ND34
49GF Score
Tandem Diabetes Care Inc BSP:T2ND34
Other Current Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tandem Diabetes Care Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

What does a Other Current Liabilities of R$697 Mil mean?
Tandem Diabetes Care (BSP:T2ND34) has a Other Current Liabilities of R$697 Mil as of Jun. 2026. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Tandem Diabetes Care.
Is Tandem Diabetes Care's Other Current Liabilities too high?
Tandem Diabetes Care's current Other Current Liabilities is R$697 Mil. Overall, Tandem Diabetes Care has a GF Score™ of 49/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Tandem Diabetes Care's Other Current Liabilities compare to CNMD and ATEC?
Tandem Diabetes Care's Other Current Liabilities of R$697 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Liabilities for a Medical Devices & Instruments company?
A good Other Current Liabilities depends on the Medical Devices & Instruments industry context. However, Other Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Liabilities mean?
A high Other Current Liabilities can signal that a stock is expensive relative to its fundamentals. Other current liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Tandem Diabetes Care. Tandem Diabetes Care's current Other Current Liabilities is R$697 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tandem Diabetes Care stock overvalued right now?
Based on GuruFocus' analysis, Tandem Diabetes Care (BSP:T2ND34) is currently considered Modestly Undervalued. The stock's GF Value™ is R$8.36, compared to a current price of R$5.98 — trading 28.5% below its estimated fair value. The current Other Current Liabilities is R$697 Mil. Tandem Diabetes Care's overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Liabilities calculated?
Other Current Liabilities is calculated from a company's financial statements. For Tandem Diabetes Care (BSP:T2ND34), the current Other Current Liabilities is R$697 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tandem Diabetes Care (BSP:T2ND34) Overvalued in 2026?

Based on GuruFocus' analysis, Tandem Diabetes Care stock appears to be undervalued. The current stock price of R$5.98 is trading 28.5% below its estimated GF Value™ of R$8.36. GuruFocus considers Tandem Diabetes Care to be Modestly Undervalued.

Key valuation signals for BSP:T2ND34:

  • Other Current Liabilities: R$697 Mil
  • GF Value™: R$8.36 vs. price of R$5.98 (28.5% below fair value)
  • GF Score™: 49/100 with 5 warning signs

No single metric tells the full story. See the BSP:T2ND34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Tandem Diabetes Care Business Description

Other Exchanges TNDM:USA0M0F:UKTD5A:Germany
Address 12400 High Bluff Drive, San Diego, CA, USA, 92130
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
49GF Score

Get the complete analysis for BSP:T2ND34

Other Current Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$5.98
Price
R$8.36
GF Value